Biopharma SHAKTI: India's Biologics Ambition & Future of Affordable Patient Care (2026 Guide)
India's Biopharma SHAKTI initiative aims to launch 100 biologics by 2047 while making advanced therapies more affordable through domestic innovation and biosimilar manufacturing. If supported by strong regulation, public procurement, and healthcare infrastructure, it could significantly improve patient access to life-saving biologic medicines across India.
Biopharma SHAKTI and India's Biologics Ambition: What It Means for Patients at the Clinic Door
India's biologics revolution is no longer just an industrial policy—it is becoming a patient access strategy. Through Biopharma SHAKTI, the Government of India aims to strengthen innovation, boost domestic biologics manufacturing, and make advanced therapies more affordable for millions of patients. If implemented effectively, the initiative could reshape access to life-saving biologics across cancer, diabetes, autoimmune diseases, and rare disorders.
What Is Biopharma SHAKTI?
Biopharma SHAKTI is India's flagship roadmap for expanding the country's biologics ecosystem under the broader vision of Viksit Bharat and Swasth Bharat. Announced during the 2nd Pharma Summit & Awards 2026 organized by ASSOCHAM, the initiative aims to facilitate the launch of 100 biologics by 2047, coinciding with India's centenary of independence.
Speaking at the summit, Union Minister of State for Chemicals & Fertilizers Ms. Anupriya Patel highlighted the dual objective of promoting innovation while ensuring affordable access to advanced biological medicines for Indian patients.
The initiative brings together multiple government programs, including:
PRIP Scheme
Supports research and innovation across the pharmaceutical value chain.
National Biopharma Mission
Strengthens India's biologics research ecosystem and translational capabilities.
BIRAC Funding Programs
These include:
- Biotech Ignition Grant (BIG)
- Small Business Innovation Research Initiative (SBIRI)
- Biotechnology Industry Partnership Programme (BIPP)
Collectively, these initiatives support startups, research institutions, and pharmaceutical manufacturers from discovery through commercialization.
Why India Is Investing in Biologics
Biologics are medicines produced using living cells rather than conventional chemical synthesis. They include:
- Monoclonal antibodies
- Insulin analogues
- Vaccines
- Erythropoietin
- CAR-T therapies
- Gene therapies
Unlike conventional medicines, biologics are highly complex and cannot be copied exactly. Instead, manufacturers develop biosimilars, which are highly comparable versions offering similar efficacy and safety at significantly lower costs.
With biologics expected to account for nearly 40% of global prescription medicines by 2031, India is positioning itself to become a global leader in affordable biologic manufacturing, much as it did with generic medicines.
India's Growing Biosimilar Leadership
India already has one of the world's strongest biosimilar industries.
Leading manufacturers have successfully developed biosimilars for:
- Trastuzumab
- Bevacizumab
- Adalimumab
- Insulin Glargine
These products are exported to highly regulated markets including the United States, Europe, Australia, and Japan, demonstrating India's world-class manufacturing capabilities.
However, domestic adoption remains inconsistent due to:
Limited Prescriber Awareness
Many clinicians remain cautious about switching patients between originator biologics and biosimilars.
Procurement Challenges
Several State government formularies still exclude many biosimilars from routine procurement.
Pharmacovigilance Gaps
A stronger biologics-specific safety monitoring system is essential for wider clinical confidence.
How Biopharma SHAKTI Can Improve Patient Access
The initiative focuses not only on manufacturing but also on improving healthcare access.
Cancer Care
Affordable biosimilars of trastuzumab have already reduced treatment costs for HER2-positive breast cancer.
Expanding their inclusion under Ayushman Bharat PM-JAY could dramatically improve affordability for thousands of women across India.
Diabetes Management
Long-acting insulin analogues such as insulin glargine offer better glycaemic control with fewer episodes of hypoglycaemia.
Broader public procurement could benefit India's rapidly growing diabetic population.
Autoimmune Diseases
Patients with rheumatoid arthritis, ankylosing spondylitis, psoriasis, and inflammatory bowel disease often remain undertreated because biologics are expensive.
Affordable biosimilars could significantly improve long-term disease control.
Rare Diseases
Enzyme replacement therapies remain prohibitively expensive for most Indian families.
Domestic development of these biologics could transform care for patients living with rare genetic disorders.
Biopharma SHAKTI and India's Healthcare System
India's healthcare sector continues to expand rapidly, supported by increased public health investments and wider insurance coverage.
With Ayushman Bharat covering millions of beneficiaries, policymakers now face an important challenge:
Will insurance schemes also cover next-generation biologics, or remain limited to older therapies?
Biopharma SHAKTI provides an opportunity to ensure advanced therapies become part of mainstream public healthcare.
Key Challenges Ahead
Regulatory Strengthening
India's regulatory processes must evolve alongside innovation, ensuring faster yet scientifically rigorous approvals for biologics.
Clinician Education
Continuous medical education on biosimilars, switching practices, and pharmacovigilance will be critical for wider adoption.
Manufacturing Infrastructure
Advanced biologics require:
- Cold-chain logistics
- Specialized production facilities
- Skilled scientific workforce
Expanding these capabilities remains a major priority.
Improving Access Beyond Metro Cities
Tier-II and Tier-III cities are witnessing rapid healthcare growth.
Strengthening biologics distribution and cold-chain networks will be essential for equitable nationwide access.
Why Biopharma SHAKTI Matters
India transformed global healthcare by becoming the world's largest supplier of affordable generic medicines.
Biopharma SHAKTI seeks to replicate that success in the biologics era.
Its success will ultimately be measured not by the number of biologics launched, but by whether patients can actually receive life-saving treatments without catastrophic financial burden.
For patients living with rheumatoid arthritis, breast cancer, diabetes, autoimmune diseases, and rare disorders, affordable biologics represent more than scientific progress—they represent hope, longer lives, and better quality of life.
Conclusion
Biopharma SHAKTI is more than an industrial development strategy; it is a long-term healthcare access mission. By strengthening research, encouraging domestic manufacturing, supporting biosimilar innovation, and integrating biologics into public health programs, India has the opportunity to become a global leader in affordable advanced medicines. The coming decades will determine whether this ambitious vision translates into meaningful improvements at the clinic door for every patient who needs these life-changing therapies.
Team Healthvoice
#BiopharmaIndia #AffordableHealthcare
